SEC Form 4 · accession 0001209191-17-002389
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Lian
Officer — President & CEO · Director
Period of report
Jan 5, 2017
Accepted (ET)
Jan 5, 2017 · 7:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607678
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.23 | Jan 5, 2017 | A | 250,000 | A | Jan 5, 2018 | Jan 5, 2027 | Common Stock | 250,000 | 250,000 | D |
| Stock Option (Right to Buy)F2 | $1.23 | Jan 5, 2017 | A | 34,931 | A | Jan 5, 2017 | Jan 5, 2027 | Common Stock | 34,931 | 34,931 | D |
Explanation of responses
- F125% of the shares subject to the option will vest on each anniversary of the grant date.
- F2The Reporting Person's employment agreement with the Issuer entitles him to an annual cash bonus. The Reporting Person voluntarily elected to be paid 25% of his 2016 annual cash bonus in the form of an option to purchase shares of common stock of the Issuer.